GLG News by Aranesp Prescribers (US)

Revlimid has activity in Chronic Lymphatic Leukemia (CLL) in addition to myeloma and myelodysplasia.

Higher recurrance rate???!!!

A single payer, national system does work, but may not necessarily be in the best interest of all parties.   Yes this type of system is 'free' to the users, but is funded through higher taxes than paid in the US.

     While no slam dunk cures are noted, drugs such as Avastin (Genentech), Temodar (Schering-Plough) &  Avant/Pfizer  vaccines  are making an impact on  "Brain Cancer"  survival.

" Conclusions: Cetuximab does not appear to add to treatment efficacy when combined with gemcitabine and docetaxel in advanced NSCLC. A high rate of severe cetuximab HSRs necessitated trial closure at our Nashville site." Not very promising.

Low cost generics to be produced in China will lower drug costs.

As world economies improve more money will be spent globally on cancer care expanding potential markets

Cancer patients frequently develop neuropathy as a results of chemotherapy agents including oxaliplatin, paclitaxel, vinca alkaloids, and Velcade.  Because many such patients have extended survival or receive treatment with curative intent, the resultant neuropathy can limit quality of life significantly....

Carfilzomib is a nvelo prteosome inhibitor.  Bortezomib, the only proteosome inhibitor that is currently FDA approve, has shown significant activity in myeloma and mantle cell NHL and is being tested in other hematologic malignancies.  If Carfilzomib has improved toxicty and greater efficacy...

Two papers, the one above, and http://jco.ascopubs.org/cgi/content/full/26/15/2450 reveal somewhat conflicting data on AstraZeneca's Iressa that was until now on the "back burner" due to Genentech's Tarceva, that had better response data than Iressa in separate trials On one hand the first paper points...